Skip to main content
SpringerLink
Log in

The Mouse Model of Respiratory Syncytial Virus Disease

  • Chapter
  • First Online:
Challenges and Opportunities for Respiratory Syncytial Virus Vaccines

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 372))

Abstract

The laboratory mouse is the species of choice for most immunological studies, ranging from simple vaccine testing to the intricate dissection of fundamental immunopathogenic mechanisms. Although not fully mouse adapted, some strains of respiratory syncytial virus (RSV) replicate in the murine respiratory tract and induce specific T and B cell responses. Passive transfer of neutralising antibody is protective and assist in viral clearance. In addition, many of RSV’s complex behaviours are recapitulated in the mouse (including enhancement of disease by vaccination and delayed effects of neonatal infection). However, human studies remain essential to confirm or refute predictions from animal models.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alwan WH, Kozlowska WJ, Openshaw PJM (1994) Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 179:81–89

    Article  CAS  PubMed  Google Scholar 

  • Alwan WH, Record FM, Openshaw PJM (1993) Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol 150:5211–5218

    CAS  PubMed  Google Scholar 

  • Bhoj VG, Sun Q, Bhoj EJ, Somers C, Chen X, Torres JP, Mejias A, Gomez AM, Jafri H, Ramilo O, Chen ZJ (2008) MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci USA 105:14046–14051

    Article  CAS  PubMed  Google Scholar 

  • Cannon MJ, Openshaw PJM, Askonas BA (1988) Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168:1163–1168

    Article  CAS  PubMed  Google Scholar 

  • Connors M, Giese NA, Kulkarni AB, Firestone C-Y, Morse HC III, Murphy BR (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin- 4 (IL-4) and IL-10. J Virol 68:5321–5325

    CAS  PubMed Central  PubMed  Google Scholar 

  • Culley FJ, Pollott J, Openshaw PJ (2002) Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 196:1381–1386

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP (2009) Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15:34–41

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Goetsch L, Plotnicky-Gilquin H, Champion T, Beck A, Corvaia N, Stahl S, Bonnefoy JY, Nguyen TN, Power UF (2000) Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate. Vaccine 18:2735–2742

    Article  CAS  PubMed  Google Scholar 

  • Graham BS (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239:149–166

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Graham BS, Bunton LA, Wright PF, Karzon DT (1991) Reinfection of mice with respiratory syncytial virus. J Med Virol 34:7–13

    Article  CAS  PubMed  Google Scholar 

  • Graham BS, Perkins MD, Wright PF, Karzon DT (1988) Primary respiratory syncytial virus infection in mice. J Med Virol 26:153–162

    Article  CAS  PubMed  Google Scholar 

  • Graham BS, Wright PF, Karzon DT (1986) Enhanced illness in BALB/c mice following nasal infection with respiratory syncytial virus (RSV) after intramuscular priming with live or formalin inactivated RSV. ICAA Abs 78:110

    Google Scholar 

  • Hall CB, Geiman JM, Biggar R, Kotok D, Hogan PM, Douglas RG (1976) Respiratory syncytial virus infection within families. N Engl J Med 294:414–419

    Article  CAS  PubMed  Google Scholar 

  • Harker J, Bukreyev A, Collins PL, Wang B, Openshaw PJ, Tregoning JS (2007) Virally delivered cytokines alter the immune response to future lung infections. J Virol 81:13105–13111

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Harker JA, Lee DC, Yamaguchi Y, Wang B, Bukreyev A, Collins PL, Tregoning JS, Openshaw PJ (2010) Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol 84:5294–5302

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hussell T, Openshaw PJM (1997) Genetic influences on the induction of eosinophilic pathology during viral infection. Immunol Lett 56:305–306

    Google Scholar 

  • Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:108–119

    Article  CAS  PubMed  Google Scholar 

  • Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de HA (2012) Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 7:e36812

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, Baker JR Jr, Lukacs NW (2011) A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE 6:e21823

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Loebbermann J, Thornton H, Johansson C, Openshaw PJM (2013) Defective immunoregulation in vaccine-augmented viral lung disease, restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci USA 110(8):2987–2992

    Article  CAS  PubMed  Google Scholar 

  • Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12:905–907

    Article  CAS  PubMed  Google Scholar 

  • Mosmann TR, Cherwinski HM, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357

    CAS  PubMed  Google Scholar 

  • Openshaw PJM, Clarke SL, Record FM (1992) Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4:493–500

    Article  CAS  PubMed  Google Scholar 

  • Polack FP, Teng MN, Collins L, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA (2002) A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease. J Exp Med 196:859–865

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Power UF, Nguyen TN, Rietveld E, De Swart RL, Groen J, Osterhaus AD, De Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N, Bonnefoy JY (2001) Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184:1456–1460

    Article  CAS  PubMed  Google Scholar 

  • Pribul PK, Harker J, Wang B, Wang H, Tregoning JS, Schwarze J, Openshaw PJ (2008) Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 82:4441–4448

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Prince GA, Horswood RL, Berndt J, Suffin SC, Chanock RM (1979) Respiratory syncytial virus infection in inbred mice. Infect Immun 26:764–766

    CAS  PubMed Central  PubMed  Google Scholar 

  • Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM (2010) Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 65:1045–1052

    Article  PubMed  Google Scholar 

  • Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ, Collins AP, Hughes M, Jebbett T (1984a) Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137–142

    CAS  PubMed  Google Scholar 

  • Taylor G, Stott EJ, Hughes M, Collins AP (1984b) Respiratory syncytial virus infection in mice. Infect Immun 43(2):649–655

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wang SZ, Xu H, Wraith A, Bowden JJ, Alpers JH, Forsyth KD (1998) Neutrophils induce damage to respiratory epithelial cells infected with respiratory syncytial virus. Eur Respir J 12:612–618

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments and dedication

I thank the Wellcome Trust (UK) for providing generous financial support for over the past 25 years, and all past and present laboratory members for their inestimable input and commitment. I would like apologise to all whose work has been necessary to omit from this brief review, which I dedicate to Dr Brigitte Askonas.

Author information

Authors and Affiliations

  1. National Heart and Lung Institute, Norfolk Place, St Mary’s Campus, Imperial College London, London, W2 1PG, UK

    Peter J. Openshaw

Authors
  1. Peter J. Openshaw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Openshaw .

Editor information

Editors and Affiliations

  1. Department of Pediatrics and Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA

    Larry J. Anderson

  2. Vaccine Research Center, NIH Natl. Inst. of Allergy & Infect. Dis., Bethesda, Maryland, USA

    Barney S. Graham

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Openshaw, P.J. (2013). The Mouse Model of Respiratory Syncytial Virus Disease. In: Anderson, L., Graham, B. (eds) Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology, vol 372. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38919-1_18

Download citation

Publish with us

Policies and ethics

Search

Navigation